RedHill Biopharma (RDHL) Non Operating Income (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Non Operating Income data on file, last reported at $47.5 million in Q2 2023.

• Non Operating Income for Q2 2023 came in at $47.5 million, up 1760.93% year-over-year; the trailing twelve-month figure through Jun 2023 was -$8.9 million (up 53.17% YoY), and the FY2025 annual result was -$138000.0, down 102.02% from the prior year.
• Non Operating Income advanced to $47.5 million in Q2 2023 per RDHL's latest filing, from -$21.2 million in the prior quarter.
• Over five years, Non Operating Income peaked at $47.5 million in Q2 2023 and troughed at -$63.9 million in Q4 2022.
• A 5-year average of -$397200.0 and a median of $3.9 million in 2022 frame the typical range for Non Operating Income.
• On a YoY basis, Non Operating Income climbed as much as 3241.13% in 2021 and fell as far as 739.07% in 2021.
• A 5-year view of Non Operating Income shows it stood at $657000.0 in 2019, then surged by 603.65% to $4.6 million in 2020, then slumped by 739.07% to -$29.5 million in 2021, then slumped by 116.18% to -$63.9 million in 2022, then soared by 174.36% to $47.5 million in 2023.
• Business Quant data shows RDHL's Non Operating Income at $47.5 million in Q2 2023, -$21.2 million in Q1 2023, and -$63.9 million in Q4 2022.